Cargando…

Missing clinical trial data: the evidence gap in primary data for potential COVID-19 drugs

BACKGROUND: Several drugs are being repurposed for the treatment of the coronavirus disease 2019 (COVID-19) pandemic based on in vitro or early clinical findings. As these drugs are being used in varied regimens and dosages, it is important to enable synthesis of existing safety data from clinical t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rodgers, Florence, Pepperrell, Toby, Keestra, Sarai, Pilkington, Victoria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809643/ https://www.ncbi.nlm.nih.gov/pubmed/33451350 http://dx.doi.org/10.1186/s13063-021-05024-y

Ejemplares similares

Making a COVID-19 vaccine that works for everyone: ensuring equity and inclusivity in clinical trials
por: Pepperrell, Toby, et al.
Publicado: (2021)

Who funded the research behind the Oxford–AstraZeneca COVID-19 vaccine?
por: Cross, Samuel, et al.
Publicado: (2021)

Adoption of World Health Organization Best Practices in Clinical Trial Transparency Among European Medical Research Funder Policies
por: Bruckner, Till, et al.
Publicado: (2022)

A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic?
por: Pilkington, Victoria, et al.
Publicado: (2020)

Improving clinical trial transparency at UK universities: Evaluating 3 years of policies and reporting performance on the European Clinical Trial Register
por: Mirjam Keestra, Sarai, et al.
Publicado: (2022)

Global COVID-19 Vaccine Inequity: Failures in the First Year of Distribution and Potential Solutions for the Future
por: Pilkington, Victoria, et al.
Publicado: (2022)

Clinical trial reporting performance of thirty UK universities on ClinicalTrials.gov—evaluation of a new tracking tool for the US clinical trial registry
por: Keestra, Sarai Mirjam, et al.
Publicado: (2021)

1946. Efficacy of Approved versus Unapproved Vaccines for SARS-CoV-2 Infection in Randomised Blinded Clinical Trials
por: Navarro, Andrea Perez, et al.
Publicado: (2022)

Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19
por: Pepperrell, Toby, et al.
Publicado: (2020)

Efficacy of Approved Versus Unapproved Vaccines for Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Randomized Blinded Clinical Trials
por: Perez Navarro, Andrea, et al.
Publicado: (2022)

Will Big Data Close the Missing Heritability Gap?
por: Kim, Hwasoon, et al.
Publicado: (2017)

Structural violence and the biomedical innovation system: what responsibility do universities have in ensuring access to health technologies?
por: Keestra, Sarai
Publicado: (2021)

Stereotyping and the treatment of missing data for drug and alcohol clinical trials
por: Arndt, Stephan
Publicado: (2009)

Public Risk-Taking and Rewards During the COVID-19 Pandemic - A Case Study of Remdesivir in the Context of Global Health Equity
por: Wimmer, Sabrina, et al.
Publicado: (2020)

Missing data in clinical trials: Pitfalls and remedies
por: Kaushal, Sandeep
Publicado: (2014)

Characterization of missing data patterns and mechanisms in longitudinal composite outcome trial in rheumatoid arthritis
por: Ibrahim, Fowzia, et al.
Publicado: (2022)

How Missing Discharge Diagnosis Data in Syndromic Surveillance Leads to Coverage Gaps
por: Dotson, Kayley, et al.
Publicado: (2018)

Missing data as data
por: Basiri, Anahid, et al.
Publicado: (2022)

The ghost in the data: Evidence gaps and the problem of fake drugs in global health research
por: Hodges, Sarah, et al.
Publicado: (2020)

Intricacy of missing data in clinical trials: Deterrence and management
por: Singhal, Richa, et al.
Publicado: (2014)

The Missing Medians: Exclusion of Ordinal Data from Meta-Analyses
por: Cumming, Toby B., et al.
Publicado: (2015)

Sensitivity analyses for trials with missing data, assuming missing not at random mechanisms
por: Leurent, Baptiste, et al.
Publicado: (2013)

Cabotegravir—Global Access to Long-Acting Pre-exposure Prophylaxis for HIV
por: Pepperrell, Toby, et al.
Publicado: (2022)

Addressing persistent evidence gaps in cardiovascular sex differences research – the potential of clinical care data
por: Bots, Sophie H., et al.
Publicado: (2023)

Reinterpreting patterns of variation in human thyroid function: An evolutionary ecology perspective
por: Keestra, Sarai, et al.
Publicado: (2020)

Filling the gap in functional trait databases: use of ecological hypotheses to replace missing data
por: Taugourdeau, Simon, et al.
Publicado: (2014)

Strategies for handling missing data in randomised trials
por: White, Ian R
Publicado: (2011)

Problems in dealing with missing data and informative censoring in clinical trials
por: Shih, Weichung Joseph
Publicado: (2002)

Normal Theory GLS Estimator for Missing Data: An Application to Item-Level Missing Data and a Comparison to Two-Stage ML
por: Savalei, Victoria, et al.
Publicado: (2017)

A systematic review of randomised controlled trials in rheumatoid arthritis: the reporting and handling of missing data in composite outcomes
por: Ibrahim, Fowzia, et al.
Publicado: (2016)

Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls
por: Sterne, Jonathan A C, et al.
Publicado: (2009)

Clinical trial data reuse – overcoming complexities in trial design and data sharing
por: Wilkinson, Toby, et al.
Publicado: (2019)

Reported reasons for missing data and the interplay with trial setting
por: Kearney, Anna, et al.
Publicado: (2015)

Barriers to Worldwide Access for Paxlovid, a New Treatment for COVID-19
por: Pepperrell, Toby, et al.
Publicado: (2022)

Missing data in randomised controlled trials of rheumatoid arthritis drug therapy are substantial and handled inappropriately
por: Khan, Nasim A, et al.
Publicado: (2021)

Imputation methods for missing outcome data in meta-analysis of clinical trials
por: Higgins, Julian PT, et al.
Publicado: (2008)

A review of the handling of missing longitudinal outcome data in clinical trials
por: Powney, Matthew, et al.
Publicado: (2014)

Strategies for Dealing with Missing Data in Clinical Trials: From Design to Analysis
por: Dziura, James D., et al.
Publicado: (2013)

SLE clinical trials: impact of missing data on estimating treatment effects
por: Kim, Mimi, et al.
Publicado: (2019)

Analyses of drug combinations using missing data shortens trial periods in phase I/II oncology trials
por: Yada, Shinjo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6i6us06i793ukcvs5a88qho8d9